CD3-specific antibodies: a portal to the treatment of autoimmunity.
Nat Rev Immunol
; 7(8): 622-32, 2007 Aug.
Article
em En
| MEDLINE
| ID: mdl-17641665
ABSTRACT
Targeted immunotherapies hold great promise for the treatment and cure of autoimmune diseases. The efficacy of CD3-specific monoclonal antibody therapy in mice and humans stems from its ability to re-establish immune homeostasis in treated individuals. This occurs through modulation of the T-cell receptor (TCR)-CD3 complex (also termed antigenic modulation) and/or induction of apoptosis of activated autoreactive T cells, which leaves behind 'space' for homeostatic reconstitution that favours selective induction, survival and expansion of adaptive regulatory T cells, which establishes long-term tolerance. This Review summarizes the pre-clinical and clinical studies of CD3-specific monoclonal antibody therapy and highlights future opportunities to enhance the efficacy of this potent immunotherapeutic.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Muromonab-CD3
/
Complexo CD3
/
Diabetes Mellitus Tipo 1
/
Imunoterapia
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Nat Rev Immunol
Assunto da revista:
ALERGIA E IMUNOLOGIA
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
França